Researchers at Momenta Pharmaceuticals are looking for adults with generalized myasthenia gravis (gMG) to participate in a phase 2 study. The goal of the study is to evaluate the safety and efficacy of nipocalimab in patients who did not respond to standard of care. This therapy may improve function by lowering the levels of antibodies . . .
MDA’s new Medical Education department was established in response to the growing need for clinician education in neuromuscular diseases. We are pleased to present our first program highlighting amyotrophic lateral sclerosis (ALS): a PowerPoint slide deck. ALS is a motor neuron disease that leads to the widespread loss of muscle use. Patients diagnosed with ALS . . .
At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with Duchenne muscular dystrophy (DMD), as well as their caregivers and loved ones, to attend the MDA Engage DMD Symposium taking place Nov. . . .
At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with Charcot-Marie-Tooth disease (CMT), as well as caregivers and loved ones, to attend the MDA Engage CMT Symposium taking place Nov. 9 in . . .
At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with myotonic dystrophy (DM), as well as caregivers and loved ones, to attend the MDA Engage Myotonic Dystrophy Symposium taking place Nov. 9 . . .
We invite you to attend an upcoming virtual MDA Engage Becker Muscular Dystrophy Symposium where we will share information from experts in the field about Becker muscular dystrophy (BMD). The online event will take place Oct. 26 from noon-4 p.m. ET. Event chair Dr. Paula Clemens from the University of Pittsburgh School of Medicine and . . .
On Oct. 2, NS Pharma Inc. (a wholly-owned US subsidiary of Nippon Shinyaku Co. Ltd.) submitted a rolling New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its exon-skipping therapy under development, viltolarsen (previously NS-065/NCNP-01), to treat Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. On Sept. 26, Nippon Shinyaku . . .
At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with myasthenia gravis (MG), as well as caregivers and loved ones, to attend the MDA Engage MG Symposium taking place on Nov. 2 . . .
Michael Shy, PhD, professor of Neurology and Pediatrics at the University of Iowa, was awarded an MDA Clinical Research Network Grant (CRNG) totaling $423,413 over three years to further develop the Inherited Neuropathies Consortium (INC), a network of clinical investigators dedicated to developing the infrastructure necessary to evaluate therapies for patients with inherited peripheral neuropathies, . . .
This week, Santhera released a letter to the Duchenne muscular dystrophy (DMD) community regarding an update on Santhera’s DMD drug development programs and its partnership with ReveraGen. The full letter follows. Letter to the DMD community from Santhera: Dear Duchenne community, It was great to connect with so many of you at the Parent Project . . .
